
Los Angeles wildfires may be linked to 440 deaths, new research estimates
While officials reported that the Palisades and Eaton fires directly killed at least 30 people when they incinerated parts of Los Angeles County, the blazes may be linked to 410 additional deaths from January 5 to February 1, according to research published Wednesday in the The Journal of the American Medical Association. That would make for a total of 440 wildfire-related deaths, according to the study.
'These additional deaths likely reflect a combination of factors, including increased exposure to poor air quality and health care delays and interruptions,' the study says.
The wildfires' impact on his loved ones motivated Andrew Stokes, a mortality demographer and one of the authors of the study, to probe for excess deaths.
'Having had many family and friends who were directly affected made me feel compelled to look into this further, using my expertise as a demographer and a person who studies mortality statistics,' the Boston University associate professor told CNN.
The new findings highlight the need to quantify just how deadly wildfires and other climate-related emergencies can be beyond direct fatalities. The emergencies can have long-term health effects that extend well beyond the disaster itself, experts say.
Years ago, Stokes evaluated the excess deaths during the pandemic after many deaths went uncounted, he said. After developing models to understand the true toll of the virus, Stokes used that expertise to look at the true mortality burden of natural disasters such as the Los Angeles wildfires.
Along with deaths directly related to the wildfire, the researchers counted deaths partially and indirectly attributed to the wildfires. That includes lung or heart conditions exacerbated by smoke or stress, disruptions to health systems and mental health impacts, according to the study.
To conduct the study, the researchers compared recorded deaths in Los Angeles County from January to February with figures from previous years, excluding 2020 to 2023 due to the COVID-19 pandemic. That helped researchers estimate how many deaths would have been expected in that time period had no wildfires occurred, Stokes said.
They then calculated excess deaths as the difference between observed and expected deaths, according to the study.
'In Los Angeles County, weekly deaths consistently exceeded expected deaths during the period from January 5 to February 1, 2025,' the study says.
A total of 6,371 deaths were observed in the county, compared with 5,931 expected deaths, according to the study. This means that nearly 7% of the recorded deaths in Los Angeles County were excess deaths linked to the wildfires.
Stokes said he was 'really surprised and alarmed' at the findings. 'The magnitude of the underreporting in the official data is just very severe,' he said.
But he hopes that quantifying the excess deaths can spur authorities to provide more assistance to those still grappling with the devastation.
The researchers note that the data is preliminary and the toll could grow.
'That 440 value that we estimate is clearly the lower bound, because we only look at the first weeks after the wildfire started,' Stokes said. 'These medium and long- term effects … could manifest over time as people develop wildfire related diseases.'
Future studies should investigate the longer-term health impacts of the wildfires and the specific causes of excess wildfire deaths, the researchers said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合

Yahoo
29 minutes ago
- Yahoo
Spokane astronaut Anne McClain, Crew-10 safely splashdown on 'greatest planet in the solar system'
Aug. 9—Spokane native and NASA astronaut Anne McClain has now safely traveled to space and back, twice. McClain, a U.S Army Colonel and commander of NASA's SpaceX Crew-10 mission, splashed down off the coast of San Diego, California, Saturday morning at 8:33 a.m. Pacific Time alongside her team of space travelers. The crew's arrival back on Earth marks the end of a 148-day round-trip, with all but two of those days spent aboard the International Space Station conducting groundbreaking research, maintenance and educational downlinks, much like the one McClain held with Spokane students at her Alma Mater Gonzaga Preparatory School in May. On Tuesday, the members of Crew-10 each took a moment to reflect on their time in microgravity at a changing of the guard ceremony with Crew-11, who arrived last week. The predominant theme was gratitude: for the experience with one another, the support of those on Earth and, as McClain put it, "to represent humanity." "All of us are keenly aware that we may never get to do this again," McClain said. "We've been very pensive over the last few days, understanding what we have all got to be a part of. And we know that there's some tumultuous times on Earth. ... We want this mission, our mission, to be a reminder of what people can do when we work together, when we explore together." Returning with McClain were NASA astronaut Nichole Ayers, Roscosmos cosmonaut Kirill Peskov and astronaut Takuya Onishi of the Japan Aerospace Exploration Agency. Roscosmos is the Russian space agency. The world may seem different then when she left it, but their mission was only a "short snapshot" of a decades-long international collaboration for the betterment of humanity, McClain said. In November, the International Space Station will mark 25 years of being continually staffed with human crews. "I truly believe that this is one of the biggest feats of cooperation that humans have ever accomplished. It takes people from every country, all around the world, every single day, showing up to support this mission, to make it happen." McClain said the crew will be returning to Earth at a time when the geopolitical landscape is not unlike that of 40 years ago, when the idea of the International Space Station first arose amid high political tensions between global powers. "There's a lot of people that would say 'That's not going to be possible,'" McClain said. "But all it took was visionaries from all around the world to work together, to have a mustard seed of faith that something like this could be done when we work together." McClain and company landed in the Pacific Ocean Saturday aboard the SpaceX Dragon capsule that ferried them to the station, called Endurance. The trip took more than 17 hours after undocking from the ISS while roughly 260 miles above Jakarta, Indonesia. The completely autonomous return flight started at an orbiting speed of around 17,500 mph before eventually being slowed by the Endurance's thrusters in a roughly 18-minute deorbit burn, which allowed the craft to drop into the Earth's atmosphere and cut the flight speed by 100 yards per second. Temperatures around the craft reached as high as 3,500 degrees Fahrenheit due to the friction generated as the Endurance pushed and rubbed against the air around it, super heating the molecules into a plasma. A series of parachutes were deployed after the pod reached an altitude of about 18,000 feet, followed by a deployment of four larger chutes at around 6,500 feet from the Earth's surface. Contact with the Endurance cut out for approximately 7 minutes during re-entry, which happens due to intense heat and plasma buildup, a NASA spokesperson said. The crew were traveling at a speed of around 16 mph by the time they hit the water, after experiencing gravitational forces as high as 5-G's on the way down. Laying in wait for Crew-10 was the SpaceX recovery ship dubbed "Shannon," one of two crafts used to recover Dragon capsules from aquatic landing zones. Equipped with a specialized crane, a helipad, medical experts and technical crews, the ship has been used in more than 20 recovery missions since 2019. Around 9:20 a.m., the space travelers were assisted out of the Endurance as the effects of gravity washed over them for the first time in more than five months. McClain flashed several smiles, while raising her arms triumphantly, as she shakily made her way out. Crew-10 is the first to land in the Pacific as part of the space agency's commercial crew program, through which NASA partners with various companies for more cost effective human spaceflight. With their home base in Hawthorne, California, SpaceX has previously recovered capsules in the area three times , including the Axiom 4 mission, a private 20-day space flight to the station and back between June and July. The Axiom 4 crew included retired NASA astronaut Peggy Whitson, who holds the record for any American with the most days in space at 695. Whitson was on the astronaut selection committee that selected McClain in 2013, and McClain was on the 2021 selection committee that selected Ayers. McClain commemorated their cosmic reunion with a social media post and a pair of photos on July 10. "When you reach your goals, send the elevator back down!" McClain wrote. Now with two space flights under her belt, McClain has spent 352 days in space and participated in three spacewalks for a total of 18 hours and 52 minutes. She may add to that resume in the years to come as a member of the Artemis program, which seeks to return humans to the moon. But McClain indicated Tuesday that for now, she's just excited to be back on "the greatest planet in the solar system." "We've checked," she said. Solve the daily Crossword

Associated Press
an hour ago
- Associated Press
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals
NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / New to The Street, one of the nation's longest-running business television brands, will broadcast Show #683 on Bloomberg today at 6:30 PM EST. This week's episode features four dynamic companies making waves in healthcare, biotech, blockchain gaming, and sports partnerships: BioVie Inc., FLOKI, PetVivo Holdings, Inc., and NRx Pharmaceuticals, Inc. The program, airing as sponsored programming, will also mark the television commercial debut of FLOKI, introducing the fastest-growing Valhalla Game to Bloomberg's national audience. Pedro Vidal, Chief Relationship Officer of FLOKI, discusses how the FLOKI Trading Bot has become the leader on the BNB Chain, giving traders advanced, user-friendly tools to maximize opportunities in the crypto market. Vidal also highlights the Valhalla Game's explosive success, where assets acquired in-game can be used in the real world - a groundbreaking integration of gaming and blockchain utility. Gamers are already winning Vera tokens, with over 100,000 Veras minted to date. For more information, visit and Jonathan Javitt, Founder, Chairman, and CEO of NRx Pharmaceuticals (NASDAQ:NRXP), discusses the Company's recent Citizen Petition to the U.S. Food and Drug Administration (FDA) seeking the removal of benzethonium chloride from all forms of ketamine sold in the United States. Benzethonium chloride, a preservative with known toxicity, is no longer allowed in hand cleansers, topical antiseptics, and many ophthalmic products. NRx has developed a preservative-free ketamine formulation with three-year stability, filed a supporting patent, and is pursuing FDA approval, including a potential labeled indication for treating suicidal depression under the FDA Commissioner's National Priority Voucher Program. Cuong Do, President and CEO of BioVie Inc. (NASDAQ:BIVI), provides an update on two ongoing Phase 3 clinical trials for Bezisterim. The first trial targets newly diagnosed Parkinson's patients entering therapy for the first time - potentially making Bezisterim the first new therapy for Parkinson's disease in more than 50 years. The second trial focuses on long COVID, specifically how Bezisterim may alleviate brain fog and fatigue, conditions affecting an estimated 17 million Americans. Both trials are expected to deliver top-line data in the first half of 2026. John Lai, CEO of PetVivo Holdings, Inc. (NASDAQ:PETV), joins Chase Chamberlin, Managing Partner at Commonwealth, to discuss their strategic partnership in the thoroughbred horse racing industry. Together, they aim to advance equine wellness by introducing PetVivo's innovative SPRYNG™ with OsteoCushion™ Technology into elite racing circles, offering a natural solution to maintain joint health in performance horses. About New to The Street For over 16 years, New to The Street has broadcast weekly as sponsored programming on Bloomberg Television and Fox Business, conducting more than 2,000 interviews with leaders from public and private companies. The brand operates the largest and fastest-growing digital business channel, New to The Street TV on YouTube, with over 3.16 million subscribers, delivering all-business, no-ads content. As a complete media ecosystem, New to The Street combines long-form television interviews, short-form TV commercials, iconic outdoor billboards, and the largest digital business platform to deliver predictable media for companies seeking to share their stories with investors, customers, and global audiences. For more information about upcoming episodes and featured companies, visit: Media Contact: Grace Bongiorno New to The Street [email protected] SOURCE: New to The Street press release